Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

Texas MPN Workshop 2022 | An insight into ongoing trials in CMML

Eric Padron • 26 Aug 2022
Texas MPN Workshop 2022
Chronic Myelomonocytic Leukemia Leukemia Myeloproliferative Neoplasms Rare Diseases Ruxolitinib

Eric Padron, MD, H. Lee Moffitt Cancer Center, Tampa, FL, briefly discusses some ongoing trials evaluating therapeutic approaches in chronic myelomonocytic leukemia (CMML). This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Disclosures

Research Funding: Kura, Incyte, BMS
Honoraria: Blueprint, Novartis, Stem line, Taiho, Pharmaessentia

More from Eric Padron

Unanswered questions in CMML: timing of treatment initiation to delay progression
0:59
Unanswered questions in CMML: timing of treatment initiation to delay progression
Eric Padron • 22 Aug 2025
The unique challenges that underlie the lack of therapeutic advances in CMML to date
1:36
The unique challenges that underlie the lack of therapeutic advances in CMML to date
Eric Padron • 22 Aug 2025
Using molecular profiling and genomic insights to improve the management of CMML
1:18
Using molecular profiling and genomic insights to improve the management of CMML
Eric Padron • 22 Aug 2025
Updates in the field of CMML: changes in diagnostic criteria & the growing number of clinical trials
1:31
Updates in the field of CMML: changes in diagnostic criteria & the growing number of clinical trials
Eric Padron • 22 Aug 2025

Related Videos

The RT1 trial of tislelizumab plus zanubrutinib for the treatment of Richter's transformation
1:30
The RT1 trial of tislelizumab plus zanubrutinib for the treatment of Richter's transformation
Eric Padron • 7 Dec 2025
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Eric Padron • 6 Dec 2025
Top updates in CLL from ASH 2025: insights into time-limited treatment from the CLL17 trial
0:53
Top updates in CLL from ASH 2025: insights into time-limited treatment from the CLL17 trial
Eric Padron • 7 Dec 2025
Results of the ASC2ESCALATE trial of asciminib in CML-CP with one prior TKI
2:34
Results of the ASC2ESCALATE trial of asciminib in CML-CP with one prior TKI
Eric Padron • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals